PharmaCyte Biotech (PMCB) Earnings growth forecast for next year

Public company logo of pharmacyte.com (PMCB)

PharmaCyte Biotech (PMCB) leverages unique expertise in developing protective capsules for tumor combat. The expected EPS change for the coming year reflects asset revaluation dynamics, where 0.00 represents the latest metric value. While high scientific risks and the struggle for clinical trials create pressure, a diversified network of laboratories ensures the stable delivery of biomaterials.

PMCB: PharmaCyte Biotech Inc. Expected earnings per share growth for next year 07/04/2022 - 11/11/2026

PharmaCyte Biotech, Inc. (PMCB) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Chart PharmaCyte Biotech Inc.|PMCB - Consensus Target
- market capitalization details:
Market Capitalization PharmaCyte Biotech|PMCB - Enterprise Value
- book capitalization indicators:
Book Value per Share PharmaCyte Biotech|PMCB - Company Net Assets|Market Capitalization to Book Value Ratio pharmacyte.com|PMCB - Aggregate Asset Value
- debt and liquidity details:
Debt to Equity PharmaCyte Biotech|PMCB - Long-Term Liabilities to Equity|Short-Term Debt to Capital PharmaCyte Biotech Inc.|PMCB - Aggregate Debt Obligations|Debts to Book Capitalization PharmaCyte Biotech|PMCB - Company Long-Term Debts|Company Short-Term Debt PharmaCyte Biotech|Quick Liquidity pharmacyte.com
- earnings and valuation multiples information:
PMCB - Net Income|Projected Future Earnings PharmaCyte Biotech|PMCB - P/E Multiple|Forward P/E Multiple PharmaCyte Biotech Inc.|PMCB - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio PharmaCyte Biotech|PMCB - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months PharmaCyte Biotech|PMCB - Earnings per share for the last four quarters|Quarterly EPS earnings growth pharmacyte.com|PMCB - Earnings per share growth rate in current year|Expected earnings per share growth for next year PharmaCyte Biotech
Fundamental company valuation:PharmaCyte Biotech, PMCB
Core merchandise of PharmaCyte Biotech, Inc.

This indicator measures the expected earnings momentum for the coming year, smoothing out the volatility of infrequent reports to assess margin resilience against inflationary costs. The upward trend in the projected net income growth of PharmaCyte Biotech (PMCB) confirms the effective scaling of robotic laboratories and software audits, which accelerate preclinical trials for oncology drugs and reduce operational development costs.

Main competitors

Net earnings per share growth forecast for next year TriSalus Life Sciences Inc|Expected earnings per share growth for next year RenovoRx Corporation (RNXT)